ABCDx
ABCDx is a Geneva-based medtech developing blood-based biomarker point-of-care diagnostics and AI-driven decision support for stroke, traumatic brain injury, and TIA, serving hospitals, EMS providers, and stroke centers across Europe, the US, and Asia.
- Company typePrivate
- Founded2017
- HeadquartersGeneva, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What ABCDx does
ABCDx SA is a Swiss-headquartered (Geneva) medtech company founded in 2017 as a spin-off of the University of Geneva and Hospital Vall d'Hebron, developing blood-based biomarker point-of-care diagnostics for brain injuries including stroke, traumatic brain injury (TBI), and transient ischemic attack (TIA). Its product portfolio spans LVOCheck (a prehospital LVO stroke triage platform combining a triplex biomarker rapid test, smartphone-based quantitative readout, cloud infrastructure, and AI-supported decision algorithms), StrokeCheck (ischemic vs. hemorrhagic differentiation), TBICheck and VasCheck/TIACheck (H-FABP-based tests for mTBI and TIA), and the BRAINCheck App (CE-marked Software as a Medical Device that turns a smartphone into a medical-grade reader). The proprietary PanelomiX AI engine systematically identifies optimal biomarker panels with precise thresholds for targeted clinical questions.
The company monetizes via sale of point-of-care diagnostic kits and associated hardware/software (hardware sales plus recurring software/subscription from the BRAINCheck App), licensing of its biomarker IP portfolio, and strategic manufacturing partnerships (Creonate for industrialization; PolarCool for exclusive Nordic TBICheck distribution). Go-to-market combines direct enterprise field sales to hospitals, EMS, and stroke centers with regional channel partners across Europe, the US (Veranex-guided FDA pathway), and Asia. ABCDx is pre-commercial, currently in Series A fundraising, with revenue undisclosed; its primary validation evidence base exceeds 1,000 patients across prospective ambulance and hospital studies, and it has built an international patent portfolio spanning stroke, TBI, pediatric TBI, and TIA across the US, China, and Europe.
ABCDx firmographics
Firmographics- Name
- ABCDx
- Legal name
- ABCDx SA
- Website
- https://abcdx.ch
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ABCDx is a Geneva-based medtech developing blood-based biomarker point-of-care diagnostics and AI-driven decision support for stroke, traumatic brain injury, and TIA, serving hospitals, EMS providers, and stroke centers across Europe, the US, and Asia.
- Ownership category
- akta.pro rank
ABCDx industry classification
Industry- Product category
- Point-of-Care Neurodiagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071)
- akta.pro primary industry
- SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE)
- akta.pro secondary industries
- Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
Keywords
Where ABCDx is headquartered
LocationHeadquarters
- HQ city
- Geneva
- HQ country
- Switzerland
- HQ region
- Europe
Offices3 records
Markets served
ABCDx business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Point-of-Care Diagnostic Devices: Sale of blood-based biomarker diagnostic tests (LVOCheck, TBICheck, StrokeCheck) as point-of-care medical devices. Revenue from lateral flow assay kits and associated hardware/software platforms.
- Software as a Medical Device (SaMD): Revenue from BRAINCheck App and algorithmic software that provides diagnostic interpretation and patient management capabilities.
- Licensing and Intellectual Property: Non-dilutive revenue opportunities through licensing biomarker patents and IP to strategic partners. VHIR co-ownership agreement grants exclusive commercialization rights.
- Strategic Partnerships and Manufacturing: Manufacturing and technology transfer partnerships (Creonate) for product industrialization and commercialization. Revenue from product supply to manufacturing partners.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
ABCDx product offering
Product offeringCore offering
ABCDx develops and commercializes point-of-care diagnostic devices and a Software as a Medical Device (SaMD) platform that combines proprietary blood-based biomarker panels (H-FABP, GFAP, NT-proBNP, D-Dimer) with AI-driven algorithms and smartphone-based optical readouts for rapid prehospital and emergency department detection and triage of stroke (LVO, ischemic vs. hemorrhagic), mild traumatic brain injury, and transient ischemic attack.
Differentiator
Problem solved
Functional benefit
Brands
- LVOCheck: Point-of-care diagnostic platform for rapid identification of large vessel occlusion (LVO) stroke in prehospital settings, combining blood biomarkers, lateral flow test, smartphone-based reading, and algorithmic interpretation.
- StrokeCheck
- TBICheck
- TIACheck
- BRAINCheck
- DUOCheck
- VasCheck
- PanelomiX
Products and services
- LVOCheck
Quantifiable outcome
- Reduces stroke triage time from 1-2 hours to 10 minutes
- +6 more outcomes
Companies that use ABCDx
Customer profileNamed customers5 records
Segments6 records
Ideal customer profiles4 records
ABCDx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature7 records
ABCDx partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered core and secondary.
- Creonate ManufacturingcoreTechnology transfer partnership for industrialization of LVOCheck platform. Creonate is supporting translation of assay know-how into robust, scalable, and quality-controlled manufacturing process suitable for pre-commercialization and market entry. Focus on lateral flow development, manufacturing transfer, and scalable production.
- Geneva UniversitycoreAcademic study partner for novel AI-powered blood test pilot study for stroke triage in ambulances, validating complete brain diagnostic platform under real-life emergency conditions.
- MinosiacoreAI-powered regulatory intelligence partnership for IVDR, ISO13485, and ISO 14971 compliance for LVO stroke diagnostic solution. Streamlines compliance roadmap with smart automation and human validation.
- Hospital Universitario Virgen Macarena/IBIScoreLead hospital in BIOSHIP-training study coordinating with 16 hospitals and 34 ambulance teams across 6 Spanish autonomous regions. Public-private partnership supported by Junta de Andalucía.
- Eureka ConsortiumcoreLandmark clinical study collaboration for stroke diagnosis combining LVOCheck biomarker test with STEMO ambulance CT scans. Published clinical study protocol in Frontiers in Neurology.
- Extra HorizoncoreDigital health partnership for development of LVOCheck digital platform including medical cloud solutions, digital health compliance, and ISO 13485:2016 and IEC/ISO 62304:2015 certified systems.
- NovarumsecondaryTechnology partner for LVOCheck digital platform providing reader technology for diagnostic results interpretation.
- PickleTechsecondaryTechnology partner for LVOCheck digital platform providing analysis and diagnostics algorithms.
- VeranexcoreMedtech consultancy partnership for comprehensive evaluation of LVOcheck in US healthcare sector and FDA regulatory process guidance. Conducting in-depth interviews with medical directors from Integrated Delivery Networks (IDNs).
- BBI SolutionscoreGlobal diagnostic assay development partner for LVOCheck rapid test development. Completed initial phases including assay optimization for H-FABP, NT-pro BNP, and D-Dimer detection on lateral flow format using human whole blood samples.
- Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)coreStrategic co-ownership agreement with top-tier Spanish research institution for patent application on markers for diagnosis of large vessel occlusion. Grants ABCDx exclusive rights to manufacture, import, export, promote, and sell products and services based on the patent. Enables sublicensing.
- Université de Genève (University of Geneva)coreExclusive lifetime license and co-ownership agreements for brain biomarker IP portfolio. Source of fundamental biomarker discovery research conducted by Prof. Sanchez's Biomedical Proteomics Group.
- FISEVIsecondaryCollaboration agreement with Neurovascular group of Hospital Universitario Virgen Macarena for implementation of stroke biomarker POCT tool using smartphone reading for prehospital diagnosis.
- Charité Universitätsmedizin BerlincoreCollaborative partner in Eurostars-funded LVOCheck project for prehospital stroke diagnostics. Conducted clinical integration activities with STEMO mobile stroke unit ecosystem for evaluation of LVOCheck solution in one of Europe's most advanced prehospital stroke infrastructures.
- FZMB GmbHsecondaryCollaborative partner in Eurostars-funded LVOCheck project contributing to assay development, algorithm development, and system validation activities.
- Precision Biosensor (South Korea)coreKorean biotech partner in Eurostars consortium for implementing stroke biomarker rapid test on Time-Resolved Fluorescence Immuno-Diagnostic platform. Listed on Korean stock exchange, operating in Asian and European hospitals. Provides platform with enhanced sensitivity and accuracy for brain biomarker detection.
- Seoul St. Mary's HospitalsecondaryClinical validation partner for rapid stroke diagnostic device. Pioneering institution in Stroke disease for test validation within Eurostars consortium.
- PolarCool ABcoreSwedish company for Nordic market distribution of TBICheck. Obtained exclusive distributor agreement for sports market and non-exclusive agreement for healthcare market in Nordic region. Provides privileged access to sports networks for TBICheck adoption.
Scale indicators10 records
Recent moves7 records
Expansion highlights7 records
ABCDx competitors and assessment
Company assessmentDirect peers
- BRAINBox Solutions: BRAINBox Solutions is developing blood-based biomarker tests combined with AI for concussion (TBI) and mild traumatic brain injury diagnosis, directly competing with ABCDx's TBICheck in the same clinical use case of mTBI rule-out and concussion triage.
- BrainScope Company: BrainScope develops FDA-cleared handheld EEG-based devices for traumatic brain injury assessment in emergency settings; it is a direct competitor in the mTBI/head-injury diagnostic space where ABCDx positions TBICheck, though using a neurophysiological rather than blood-biomarker approach.
- Biodesix: Biodesix is a blood-based diagnostics company commercializing proteomic and blood-based biomarker tests for lung disease; it is comparable to ABCDx as a blood-based diagnostics platform targeting clinical decision support with proprietary biomarker panels.
- Quanterix: Quanterix provides ultra-sensitive biomarker detection technology (Simoa platform) used in neurology and brain injury research; it overlaps with ABCDx's blood-based biomarker discovery approach and competes for the same research and clinical customer base in neuro-diagnostics.
- Viz.ai: Viz.ai provides AI-powered clinical decision support for stroke triage and LVO detection, deployed in hundreds of hospitals in the US and Europe; it competes with ABCDx's PanelomiX/LVOCheck in the prehospital and ED stroke triage workflow, though using imaging-based rather than blood-biomarker AI.
Broad incumbents
- Abbott (i-STAT / Stroke Portfolio): Abbott operates i-STAT and broader POC diagnostic platforms used in emergency and hospital settings, and has invested in stroke biomarker development; it is a broad incumbent that overlaps with ABCDx's prehospital/hospital POC diagnostic market with much larger commercial scale.
- Roche Diagnostics: Roche Diagnostics offers broad in-vitro diagnostics and blood-based testing platforms with growing neurology pipelines; it is a broad incumbent whose Elecsys platform and biomarker discovery capabilities compete with ABCDx's blood-based stroke/TBI diagnostic approach.
- Penumbra (Stroke Franchise): Penumbra is a leader in mechanical thrombectomy for acute ischemic stroke; it operates in ABCDx's downstream LVO treatment pathway and is a relevant incumbent whose thrombectomy centers are the same customers ABCDx targets for LVO patient routing.
Emerging players
- Cytox: Cytox develops blood-based biomarker and genetic assays for Alzheimer's and cognitive disorders; it overlaps with ABCDx's blood-based brain biomarker discovery and AI interpretation capabilities, though focused on dementia rather than acute stroke/TBI.
- Alamar Biosciences: Alamar Biosciences is an emerging proteomics company developing ultra-sensitive blood-based biomarker detection platforms for neurological and other diseases; it shares ABCDx's blood-biomarker-discovery-and-quantification technology approach in the neuro-diagnostic space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
ABCDx social profiles
Digital presenceABCDx financial estimates
Financial estimateRevenue estimate
Valuation estimate
ABCDx leadership team
Management profileNumber of profiles
Profiles9 records
ABCDx subsidiaries and ownership
Company hierarchySubsidiaries1 record
ABCDx funding detail
Funding detailFunding overview
Funding rounds6 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ABCDx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ABCDx
What does ABCDx do?
ABCDx develops and commercializes point-of-care diagnostic devices and a Software as a Medical Device (SaMD) platform that combines proprietary blood-based biomarker panels (H-FABP, GFAP, NT-proBNP, D-Dimer) with AI-driven algorithms and smartphone-based optical readouts for rapid prehospital and emergency department detection and triage of stroke (LVO, ischemic vs. hemorrhagic), mild traumatic brain injury, and transient ischemic attack.
Is ABCDx a public or private company?
ABCDx is a private company. It is classified as venture growth investor backed and is currently operating.
When was ABCDx founded?
ABCDx was founded in 2017. It employs 11 to 50 people.
Where is ABCDx based?
ABCDx is headquartered in Geneva, Switzerland, in the Europe region.
How does ABCDx make money?
Four revenue lines are on record. Point-of-Care Diagnostic Devices are the primary driver. The others are software as a Medical Device (SaMD), licensing and Intellectual Property and strategic Partnerships and Manufacturing.
Who are ABCDx's main competitors?
Direct peers on record are BRAINBox Solutions, BrainScope Company, Biodesix, Quanterix and Viz.ai. Broad incumbents are Abbott (i-STAT / Stroke Portfolio), Roche Diagnostics and Penumbra (Stroke Franchise). Emerging players are Cytox and Alamar Biosciences.
Does ABCDx have an API?
No public API is recorded for ABCDx.
What industry is ABCDx in?
ABCDx's product category is Point-of-Care Neurodiagnostics. Its primary akta.pro industry code is HLACANAE, SaMD – Monitoring, Triage & Risk Stratification Software, with a secondary code of HLACANAD, Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software. Its NAICS code is 621511 and its SIC code is 2835.